High Copayments Stymie Treatment Adherence in CMLHigh Copayments Stymie Treatment Adherence in CML
When the cost becomes too high, many patients with chronic myeloid leukemia (CML) skip doses or stop tyrosine kinase inhibitors altogether, even though these drug are keeping them alive. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 14, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
John Goldman obituary
Pioneer in bone-marrow transplantation for chronic myeloid leukaemia, which has enabled thousands of patients to live normal livesWhen John Goldman began his career in the 1960s, the diagnosis of chronic myeloid leukaemia (CML) carried a grim prognosis and a life expectancy of only three to five years. Today, thousands of patients have been cured or enjoy relatively normal lives because of his seminal contributions. John, who has died aged 75, pioneered bone-marrow transplantation for CML and later championed the drug imatinib that transformed the treatment of the disease.For 23 years from 1988 he was medical director of t...
Source: Guardian Unlimited Science - January 13, 2014 Category: Science Authors: George Q Daley Tags: theguardian.com Obituaries Medical research Cancer Science Source Type: news
Time to Punt on Ponatinib?Time to Punt on Ponatinib?
Dr. Michael Deininger reviews the data from ASH 2013 on ponatinib in chronic myeloid leukemia, and discusses the drug's future in view of the recent FDA decision to suspend approval. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Off and On Again Story of Ponatinib in CMLOff and On Again Story of Ponatinib in CML
Dr. Michael Deininger reviews the data from ASH 2013 on ponatinib in chronic myeloid leukemia, and discusses the drug's future in view of the recent FDA decision to suspend approval. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
New drug combination delayed disease progression for subgroup of women with metastatic breast cancer
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.Dasatinib is approved by the U.S. Food and Drug Administration for the treatment of chronic myelogenous leukemia. One of the ways it works is by blocking the activity of a protein called Src, which has been recently implicated in the spread of breast cancer to bones. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 17, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
'Deep Molecular Response' Boosts CML Survival (CME/CE)
(MedPage Today) -- A majority of patients with chronic myelogenous leukemia achieved a deep molecular response with imatinib-based therapy, which correlated with improved long-term and progression-free survival, a randomized trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 4, 2013 Category: Hematology Source Type: news
ARIAD terminates Phase III study of ponatinib in newly diagnosed CML patients
ARIAD Pharmaceuticals is terminating the Phase III EPIC ('Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia') trial of its oral drug candidate Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukaemia (CML). (Source: Drug Development Technology)
Source: Drug Development Technology - October 21, 2013 Category: Pharmaceuticals Source Type: news
ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia
Investor conference call today, October 18th, at 8:30 a.m. E.T.
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--ARIAD Pharmaceuticals, Inc. (ARIA) today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatin... Biopharmaceuticals, OncologyARIAD Pharmaceuticals, Iclusig, ponatinib, chronic myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 18, 2013 Category: Pharmaceuticals Source Type: news
New treatment regimen may prevent fatal leukemia progression
Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs, according to a study in The Journal of Experimental Medicine. Chronic myeloid leukemia (CML) is an aggressive cancer of the blood that is often treated with a drug called Imatinib (a.k.a. Gleevec). Although Gleevec is highly effective, some cancer cells can develop resistance to the drug. The mechanism that drives this resistance is not completely understood, but there is evidence that cancerous stem-like cells are particularly resistant and help to perpetuate disease... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 9, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Trial Suggests Imatinib Discontinuation Safe, Some Responses Persist
Evidence continues to mount that discontinuing imatinib treatment for chronic myeloid leukemia (CML) in the chronic phase is safe. A new phase II Dutch and Belgian study showed only about two-thirds of patients relapsed after discontinuing treatment with imatinib and cytarabine, and all patients remained sensitive to imatinib after relapse. (Source: Cancer Network)
Source: Cancer Network - September 16, 2013 Category: Cancer & Oncology Source Type: news
Dasatinib Shows Promise for Pediatric CML, ALL Patients
A phase I study of dasatinib in children and adolescents with chronic myeloid leukemia (CML) and other malignancies determined dosing for further studies and suggested the drug is well tolerated and effective in these patients. (Source: Cancer Network)
Source: Cancer Network - September 13, 2013 Category: Cancer & Oncology Source Type: news
ARIAD reaches 50 percent patient enrollment in Phase 3 EPIC trial of Iclusig
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) has announced enrollment of fifty percent of the patients planned in its randomized Phase 3 trial of Iclusig® (ponatinib) in adult patients with newly diagnosed chronic myeloid leukemia (CML). The trial, formally known as EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia), is designed to provide definitive clinical data to support regulatory approval of ponatinib in treatment-naïve CML patients... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 6, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Seeking in-depth knowledge about the mechanisms involved in ABL
Chronic Myelogenous Leukemia (CML) is a cancer of the white blood cells that is most commonly found in adults and in the elderly. Its incidence has been estimated to be 1 to 2 in 100,000 people. CML was the first cancer to be associated with a genetic abnormality, known as the Philadelphia Chromosome, which 95% of all CML patients carry in their cells. The Philadelphia Chromosome is formed by exchanges of material belonging to two distinct chromosomes, number 9 and number 22... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 30, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Anchoring ABL for a better fate
(Publicase Comunicação Científica) By providing a detailed description of the mechanisms by which ABL, a protein associated with Chronic Myelogenous Leukemia, undergoes cell death, this new study offers fresh perspectives on how cells carrying the Philadelphia Chromosome escape apoptosis and become immortal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 27, 2013 Category: Global & Universal Source Type: news
First-Line Treatment for Patients With CML in Chronic Phase: Second-Generation TKIs Are the Therapy of Choice
How often do we choose the “second best” treatment as initial therapy for our patients with cancer? The management of chronic myeloid leukemia should be no different. (Source: Cancer Network)
Source: Cancer Network - August 15, 2013 Category: Cancer & Oncology Source Type: news
